Phillip Debnam
About Phillip Debnam
Phillip Debnam serves as the Vice President of Alliance Management, a position he has held since 2021. He has extensive experience in alliance management and project management across various organizations, including Proximagen Neuroscience and Chroma Therapeutics.
Work at Adaptimmune
Phillip Debnam has been serving as the Vice President of Alliance Management at Adaptimmune since 2021. In this role, he is responsible for managing strategic partnerships and collaborations that are essential for the company's growth and innovation in the field of immunotherapy. His experience in alliance management positions him to effectively navigate complex relationships and ensure alignment between Adaptimmune and its partners.
Previous Experience in Alliance Management
Before joining Adaptimmune, Phillip Debnam held several positions in alliance management. He worked as an Alliance Manager from 2014 to 2015, followed by a role as Director of Alliance Management from 2016 to 2018. He then advanced to Senior Director of Alliance Management from 2019 to 2020. These roles contributed to his expertise in managing collaborations and partnerships within the biopharmaceutical industry.
Project Management Background
Phillip Debnam has a solid background in project management, having worked as a Drug Development Project Manager at Chroma Therapeutics from 2006 to 2012. His role involved overseeing drug development projects, which provided him with valuable insights into the complexities of bringing new therapies to market. Earlier in his career, he also served as a Project Manager at Proximagen Neuroscience plc for one year in 2005 to 2006.
Career Timeline
Phillip Debnam's career spans multiple roles in project and alliance management. He began as a Project Manager at Proximagen Neuroscience plc in 2005, transitioned to Chroma Therapeutics as a Drug Development Project Manager from 2006 to 2012, and then took on various alliance management roles from 2014 to 2020. His current position at Adaptimmune began in 2021, marking a significant step in his professional journey.